The Vita Coco Company Inc vs Novavax Inc — how do they compare? The Vita Coco Company Inc trades at $74.45 (market cap $4.23B), while Novavax Inc trades at $8.5 (market cap $1.38B). The key difference: The Vita Coco Company Inc is far larger — about 3.1× Novavax Inc's market cap, and The Vita Coco Company Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| COCO | NVAX | |
|---|---|---|
Market Cap | $4.23B | $1.38B |
Sector | Technology | Health |
52-Week High | $84.02 | $11.19 |
52-Week Low | $32.30 | $6.22 |
Enterprise Value | $4.04B | $889.29M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Trailing returns across standard periods
Latest headlines on both assets
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →